The FDA has determined that Sprycel (dasatinib) (used to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia [ALL]) may lead to an increased risk of dangerously high blood pressure in the arteries of the lungs (pulmonary arterial hypertension). Shortness of breath, fatigue, and swelling of the body (such as the ankles and legs) are some of the symptoms associated with PAH.
For further information on Sprycel, go to: Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension
Sprycel (dasatinib) Can Increase Risk of Pulmonary Arterial Hypertension (PAH)(10.11.11)
October 11, 2011
